Advicenne S.A. (EPA:ALDVI)

Market Cap	24.37M
Revenue (ttm)	5.90M
Net Income (ttm)	-6.21M
Shares Out	14.17M
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,359
Average Volume	26,833
Open	1.742
Previous Close	1.730
Day's Range	1.700 - 1.766
52-Week Range	1.104 - 2.100
Beta	0.81
RSI	45.51
Earnings Date	Dec 19, 2025

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. wa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALDVI

Financial Performance

In 2024, Advicenne's revenue was 5.27 million, a decrease of -0.51% compared to the previous year's 5.30 million. Losses were -6.46 million, -14.13% less than in 2023.